Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to describe the efficacy of:
1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6
2. 12-week treatment of SOF/LED for all other HCV-6 populations
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Collaborator:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir